PD
ALNY icon

Point72 (DIFC)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Point72 (DIFC)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed -$270K – 1528
2025
Q1 		$270K Buy
+1,000
New +$257K 0.01% 814

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Point72 (DIFC)'s ALNY Position: Q3 2025 in Review

Point72 (DIFC) increased its Alnylam Pharmaceuticals (ALNY) stake by 309% in Q3 2025, buying an estimated $132K and bringing the position to 429 shares worth $196K. The position accounts for 0.01% of the portfolio, ranked #450.

Point72 (DIFC) first reported a position in ALNY in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.55M in Q1 2024. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Point72 (DIFC) held 429 shares of Alnylam Pharmaceuticals worth $196K as of Q3 2025.
  • Point72 (DIFC) bought 324 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $132K.
  • Alnylam Pharmaceuticals made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #450 holding.
  • Point72 (DIFC) first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Alnylam Pharmaceuticals position peaked at $1.55M in Q1 2024.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.